These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

384 related articles for article (PubMed ID: 22341819)

  • 21. Influence of diethylstilbestrol, Leuprolelin (a luteinizing hormone-releasing hormone analog), Finasteride (a 5 alpha-reductase inhibitor), and castration on the lobar subdivisions of the rat prostate.
    Yamashita A; Hayashi N; Sugimura Y; Cunha GR; Kawamura J
    Prostate; 1996 Jul; 29(1):1-14. PubMed ID: 8685049
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ursolic acid reduces prostate size and dihydrotestosterone level in a rat model of benign prostatic hyperplasia.
    Shin IS; Lee MY; Jung DY; Seo CS; Ha HK; Shin HK
    Food Chem Toxicol; 2012 Mar; 50(3-4):884-8. PubMed ID: 22266360
    [TBL] [Abstract][Full Text] [Related]  

  • 23. LHRH agonists. A nonsurgical treatment for benign prostatic hyperplasia.
    Oesterling JE
    J Androl; 1991; 12(6):381-8. PubMed ID: 1722794
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dose-dependent growth inhibition in vivo of PC-3 prostate cancer with a reduction in tumoral growth factors after therapy with GHRH antagonist MZ-J-7-138.
    Heinrich E; Schally AV; Buchholz S; Rick FG; Halmos G; Mile M; Groot K; Hohla F; Zarandi M; Varga JL
    Prostate; 2008 Dec; 68(16):1763-72. PubMed ID: 18729085
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Shrinkage of experimental benign prostatic hyperplasia and reduction of prostatic cell volume by a gastrin-releasing peptide antagonist.
    Rick FG; Abi-Chaker A; Szalontay L; Perez R; Jaszberenyi M; Jayakumar AR; Shamaladevi N; Szepeshazi K; Vidaurre I; Halmos G; Krishan A; Block NL; Schally AV
    Proc Natl Acad Sci U S A; 2013 Feb; 110(7):2617-22. PubMed ID: 23359692
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antagonists of growth hormone releasing hormone (GHRH) and of bombesin/gastrin releasing peptide (BN/GRP) suppress the expression of VEGF, bFGF, and receptors of the EGF/HER family in PC-3 and DU-145 human androgen-independent prostate cancers.
    Stangelberger A; Schally AV; Varga JL; Hammann BD; Groot K; Halmos G; Cai RZ; Zarandi M
    Prostate; 2005 Aug; 64(3):303-15. PubMed ID: 15754342
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Oral exposure to low-dose bisphenol A aggravates testosterone-induced benign hyperplasia prostate in rats.
    Wu JH; Jiang XR; Liu GM; Liu XY; He GL; Sun ZY
    Toxicol Ind Health; 2011 Oct; 27(9):810-9. PubMed ID: 21415097
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibitory effect of antagonists of bombesin and growth hormone-releasing hormone on orthotopic and intraosseous growth and invasiveness of PC-3 human prostate cancer in nude mice.
    Stangelberger A; Schally AV; Varga JL; Zarandi M; Szepeshazi K; Armatis P; Halmos G
    Clin Cancer Res; 2005 Jan; 11(1):49-57. PubMed ID: 15671527
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prostate carcinoma tumor size in rats decreases after administration of antagonists of luteinizing hormone-releasing hormone.
    Redding TW; Coy DH; Schally AV
    Proc Natl Acad Sci U S A; 1982 Feb; 79(4):1273-6. PubMed ID: 6803239
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The influence of reversible androgen deprivation on serum prostate-specific antigen levels in men with benign prostatic hyperplasia.
    Weber JP; Oesterling JE; Peters CA; Partin AW; Chan DW; Walsh PC
    J Urol; 1989 Apr; 141(4):987-92. PubMed ID: 2467015
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibition of growth of experimental prostate cancer with sustained delivery systems (microcapsules and microgranules) of the luteinizing hormone-releasing hormone antagonist SB-75.
    Korkut E; Bokser L; Comaru-Schally AM; Groot K; Schally AV
    Proc Natl Acad Sci U S A; 1991 Feb; 88(3):844-8. PubMed ID: 1992476
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A selective alpha1A-adrenoceptor antagonist inhibits detrusor overactivity in a rat model of benign prostatic hyperplasia.
    Tatemichi S; Akiyama K; Kobayashi M; Yamazaki Y; Yokoyama O; Uruno T
    J Urol; 2006 Sep; 176(3):1236-41. PubMed ID: 16890732
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Editorial comment on: placebo-controlled dose-ranging phase 2 study of subcutaneously administered LHRH antagonist cetrorelix in patients with symptomatic benign prostatic hyperplasia.
    Bastian PJ
    Eur Urol; 2008 Jul; 54(1):179-80. PubMed ID: 18417273
    [No Abstract]   [Full Text] [Related]  

  • 34. Editorial comment on: placebo-controlled dose-ranging phase 2 study of subcutaneously administered LHRH antagonist cetrorelix in patients with symptomatic benign prostatic hyperplasia.
    Speakman MJ
    Eur Urol; 2008 Jul; 54(1):178-9. PubMed ID: 18417272
    [No Abstract]   [Full Text] [Related]  

  • 35. The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study.
    Roehrborn CG; Siami P; Barkin J; Damião R; Major-Walker K; Morrill B; Montorsi F;
    J Urol; 2008 Feb; 179(2):616-21; discussion 621. PubMed ID: 18082216
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Editorial comment on: placebo-controlled dose-ranging phase 2 study of subcutaneously administered LHRH antagonist cetrorelix in patients with symptomatic benign prostatic hyperplasia.
    Ficarra V; Novara G
    Eur Urol; 2008 Jul; 54(1):178. PubMed ID: 18417274
    [No Abstract]   [Full Text] [Related]  

  • 37. The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group.
    Gormley GJ; Stoner E; Bruskewitz RC; Imperato-McGinley J; Walsh PC; McConnell JD; Andriole GL; Geller J; Bracken BR; Tenover JS
    N Engl J Med; 1992 Oct; 327(17):1185-91. PubMed ID: 1383816
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New histopathological experimental model for benign prostatic hyperplasia: stromal hyperplasia in rats.
    Mori F; Oda N; Sakuragi M; Sakakibara F; Kiniwa M; Miyoshi K
    J Urol; 2009 Feb; 181(2):890-8. PubMed ID: 19095262
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antagonists of growth hormone-releasing hormone inhibit proliferation induced by inflammation in prostatic epithelial cells.
    Popovics P; Schally AV; Salgueiro L; Kovacs K; Rick FG
    Proc Natl Acad Sci U S A; 2017 Feb; 114(6):1359-1364. PubMed ID: 28123062
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibition of in vivo proliferation of androgen-independent prostate cancers by an antagonist of growth hormone-releasing hormone.
    Jungwirth A; Schally AV; Pinski J; Halmos G; Groot K; Armatis P; Vadillo-Buenfil M
    Br J Cancer; 1997; 75(11):1585-92. PubMed ID: 9184172
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.